Annex of Environmental Health in Emergencies and Disaster; page 245 - 252
Information in Tables 1–4 summarizes the actions of the World Health Organization,
the International Atomic Energy Authority, other international organizations, and local
health authorities in response to a nuclear acci...dent, in compliance with the Convention
on Early Notification and the Assistance Convention.
more
The module is currently available in English, French, Nepali, Portuguese, Russian, and Spanish
Developing protocols for use with refugees
and internally displaced persons
This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child...ren, and HIV co-infection are all fully addressed.
more
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection.... Preliminary
evidence suggests that HIV infection may increase the risk of BU disease (1–3). In the Médecins Sans Frontières project in Akonolinga, Cameroon, HIV prevalence was approximately 3–6 times higher among BU patients than the regional estimated HIV prevalence (2). Similarly in Benin and Ghana, BU
patients were 8 times and 3 times respectively more likely to have HIV infection than those without BU (1, 3). Further study is needed to clarify this association and enhance knowledge about the prevalence ofBU–HIV coinfection in endemic areas.
more
The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...und up to 3 times more often in people who had previous exposure to antiretroviral drugs. In addition, nearly half of infants newly diagnosed with HIV has HIVDR to NNRTI before initiating treatment.The high levels of observed NNRTI pretreatment HIVDR among emphasize the need to fast-track the transition to WHO-recommended dolutegravir-based ART.
more
The Sierra Leone National Infection Prevention and Control Guidelines were jointly developed and updated by the Ministry of Health and Sanitation in collaboration with the World Health Organization and the US Centers for Disease Control and Prevention.
Updated Treatment Guidelines
23 February 2022
A summary of the commitments and targets within the United Nations General Assembly’s 2021 Political Declaration on HIV and AIDS.The United Nations General Assembly’s 2021 Political Declaration on AIDS features bold global commitments and targets for 2025 that are ambitious but... achievable if countries and communities follow the evidence-informed guidance within the Global AIDS Strategy 2021–2026. This UNAIDS publication provides a summary of those commitments and targets to get every country and every community on-track to end AIDS as a public health threat by 2030
more
The toolkit provides guidance on where to get started, including the structures and resources that should be put in place at the national and health-care facility level, through a stepwise approach in low-resource settings. As the ultimate goal of an AMS programme is sustainable behaviour change in ...physicians’ antibiotic prescribing practices, the toolkit also provides detailed guidance on how to plan, perform and assess AMS interventions – including feedback on antibiotic use over time. Finally, the toolkit provides an overview of the competencies an AMS team needs to guide health-care professionals in changing their antibiotic prescribing behaviours.
Please note that this course is part of a training package, so please register for the complementary course WHO Policy Guidance on Integrated Antimicrobial Stewardship Activities so that you can complete your learning journey.
more
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... the WHO and the PAHO recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications
more
As the world recovers from the shock of the COVID-19 pandemic and reflects on lessons learnt from failure of global public health systems to contain the global outbreak of SARS-CoV-2, new infectious disease threats, caused by movement of people globally, remain omnipresent, and repeated calls for mo...re proactive action go unheeded. This is aptly shown by the unprecedented and unexpected outbreaks of human monkeypox cases and clusters since May 7, 2022, across Europe, the Americas, and Australia,
which yet again, have taken global public authorities by surprise.
more
Where are the outbreaks? What is monkeypox? Recongnizing monkeypox and more. An update on the monkeypox outbreak including protection, diagnosis, treatment.
19 August 2022. A monkeypox case investigation form (CIF) has been designed as a tool for Member States and researchers to conduct in-depth epidemiological investigation of suspected, probable and confirmed cases of monkeypox. This form allows to collect data prospectively or retrospectively for bot...h cases and their contacts. The full form is meant to serve as a tool for in-country use and the data are not required to be reported to WHO.
more
Severe bacterial infections are a leading cause of morbidity and mortality among people with advanced HIV disease, after tuberculosis and cryptococcal disease. For countries to reach the end-AIDS targets for 2030, there is a need to establish a roadmap for managing severe bacterial infections and re...duce mortality. The purpose of the meeting was to
Review the current research and implementation data on the use of prophylactic antibiotics (specifically azithromycin/macrolides) as part of the AHD package of care; To review options for preventing SBIs that are in line with goals of reducing AMR; Present the current evidence on diagnostics for SBI; Discuss research gaps and implementation challenges.
more
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional.
more
Getting on track to end AIDS as a public health threat by 2030. This new Road Map charts a way forward for country-level actions to achieve an ambitious set of HIV prevention targets by 2025. Those targets emerged from the 2021 Political Declaration on HIV and AIDS, which the United Nations General ...Assembly adopted in June 2021 and they are underpinned by the Global AIDS Strategy (2021–2026). The Strategy sets out the principles, approaches, priority action area and programmatic targets for the global HIV response
more
This Guideline, the first for the country, draws from national health sector reforms and integration agenda as outlined in the key national strategic documents. The Guide applies lessons learnt from the SRH/HIV Linkages project and its scale-up; other national experiences and from regional and globa...l evidence and guidance on high-impact interventions that promote sustainable, equitable and effective delivery of health services to achieve Universal Health coverage.
more